Literature DB >> 31447907

Early Response in Adolescents with Schizophrenia is not Associated with Remission at Six Months.

Sadot Arceo1, Rosa Elena Ulloa1.   

Abstract

OBJECTIVE: The objectives of present study were to determine the frequency of early response (ER), defined as a 20% decrease in total baseline PANSS score at three weeks and to compare the rate of symptomatic and functional remission between schizophrenic adolescents with and without ER.
METHODS: The sample included 61 patients (65% males) with a mean age of 15 (+ 1.54) y.o., 88.5% on their first episode of psychosis who were evaluated with PANSS and PSP scales y. They were evaluated with PANSS at week three and with PANSS and PSP at month six.
RESULTS: Twenty-three patients (37.7%) showed ER. There were no significant differences in the rate of symptomatic or functional remission at month six between responders and non-responders.
CONCLUSIONS: Early response to antipsychotic treatment can be observed in adolescent patients, however, it is not associated with remission at six months.

Entities:  

Keywords:  adolescents; antipsychotic; early response; remission; schizophrenia

Year:  2019        PMID: 31447907      PMCID: PMC6691793     

Source DB:  PubMed          Journal:  J Can Acad Child Adolesc Psychiatry        ISSN: 1719-8429


  11 in total

1.  Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Authors:  Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

2.  Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

Authors:  Ofer Agid; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2003-12

3.  Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia.

Authors:  Rosa-Elena Ulloa; Rogelio Apiquian; Gamaliel Victoria; Sofía Arce; Natalia González; Lino Palacios
Journal:  Schizophr Res       Date:  2015-02-26       Impact factor: 4.939

4.  Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).

Authors:  David V Sheehan; Kathy H Sheehan; R Douglas Shytle; Juris Janavs; Yvonne Bannon; Jamison E Rogers; Karen M Milo; Saundra L Stock; Berney Wilkinson
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

5.  Evidence for onset of antipsychotic effects within the first 24 hours of treatment.

Authors:  Shitij Kapur; Tamara Arenovich; Ofer Agid; Robert Zipursky; Stacy Lindborg; Barry Jones
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

6.  Standardized remission criteria in schizophrenia.

Authors:  Nancy C Andreasen
Journal:  Acta Psychiatr Scand       Date:  2006-02       Impact factor: 6.392

7.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

8.  Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.

Authors:  Stephen Z Levine; Stefan Leucht
Journal:  Schizophr Res       Date:  2012-09-18       Impact factor: 4.939

9.  Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.

Authors:  Christoph U Correll; Joan Zhao; William Carson; Ron Marcus; Robert McQuade; Robert A Forbes; Raymond Mankoski
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-06-05       Impact factor: 8.829

10.  A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients.

Authors:  A Fresán; C De la Fuente-Sandoval; C Loyzaga; M García-Anaya; N Meyenberg; H Nicolini; R Apiquian
Journal:  Schizophr Res       Date:  2005-01-01       Impact factor: 4.939

View more
  1 in total

Review 1.  Schizophrenia outcomes in the 21st century: A systematic review.

Authors:  Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner
Journal:  Brain Behav       Date:  2021-05-15       Impact factor: 2.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.